The pharmacology of leukotrienes in human airways: In vitro and in vivo studies

T. Vigano, M. T. Crivellari, M. Civelli, D. Oliva, S. Nicosia, A. Miadonna, A. Tedeschi, A. Sala, G. C. Folco

Research output: Contribution to journalArticlepeer-review


Immunological challenge of human lung parenchyma causes formation of arachidonate metabolites: prostaglandin D2 (PGD2) (70% of the formed mediators), leukotrienes E4 (LTE4) (15%) and D4 (LTD4) (10%). Leukotriene B4 (LTB4) was barely detectable (2%). Inhibition of PGD2 formation by indomethacin (15 μM) was approximately 90%, but was not accompanied by redistribution of arachidonate metabolism towards sulphidopeptide leukotrienes, as postulated for aspirin-sensitive asthma. Specific binding sites for leukotrienes C4 (LTC4) have been identified in membrane preparations of human bronchi. Binding of 3H-LTC4 is rapid (1 min) and quickly reversible following addition of excess. The sites are specific for LTC4 and competition curves fitted a two-site model. Moreover, clinical studies on specific endobronchial challenge of patients allergic to Dermatophagoides pteronyssinus, revealed narrowing of bronchial diameter and oedema of the bronchial mucosa; these symptoms were accompanied by an increase of immunoreactive-LTC4 and PGD2 present in the bronchial lavage fluids.

Original languageEnglish
JournalEuropean Respiratory Journal
Issue numberSUPPL. 6
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'The pharmacology of leukotrienes in human airways: In vitro and in vivo studies'. Together they form a unique fingerprint.

Cite this